Navigation Links
Thalidomide may stage a comeback

The controversial drug thalidomide, which was banned in 1962, is being reassessed to find out if it could again be prescribed to patients to treat rare forms of cancer and leprosy. The drug which is unlicensed in Europe was marketed in the 50s and 60s as a cure for morning// sickness. However, it was banned after mothers who took it gave birth to deformed children.

The European Agency for the Evaluation of Medicinal Products (EMEA) is now considering whether the drug should be re-licensed for use across the EU, since recent studies have suggested that thalidomide could be a weapon in the fight against cancer and could help people with AIDS and other serious diseases. EMEA officials who met representatives of thalidomide victims as part of their consultation process, are focusing on the safeguards that would be needed if the drug is re-licensed.

The agency also suggested that even if the drug is approved, it will only be used on specific patients. These include patients diagnosed with multiple myeloma, a cancer of the bone marrow, which affects about 20,000 patients in Europe each year. Earlier, Dr. Claus Newman, a specialist in birth defects stated that thalidomide is a unique drug with powerful effects potentially for harm and good and its wider licensing will require extraordinary measures.


'"/>




Page: 1

Related medicine news :

1. Thalidomide is the new approved drug for treating multiple cancers
2. Thalidomide for Tumor Treatment
3. Frozen Canadian baby stages miraculous recovery
4. Surgery for early stage prostate cancer is better than waiting
5. Drug Tarceva for End-stage Lung cancer
6. Breast Cancer in younger women can be detected at an early stage by mammograms
7. Cancer cells were killed even at reduced dose of radiation therapy in early stage Hodgkin’s.
8. Herceptin is the cure for early stages of breast cancer?
9. Genes determine the capacity to fight HIV in early stages
10. Dialysis Trust Set Up in Bangalore by End-stage Kidney Patients
11. Combining Therapies can Improve Survival for Early-stage Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Thalidomide may stage comeback

(Date:7/25/2008)...benefit ALS Therapy Alliance to be presented at Fe... WOONSOCKET, R.I., July 25 /PRNewswire/ -- CVS/pha... a record-breaking $4.4 million in just 21 days,th... ALS research. This is,the seventh year of the ann...more than $15 million for ALS research. This year,...
(Date:7/25/2008)... New program delivers immediate cost s...hour telephone access to language interpreters] t...ltilingual solutions. , W...reg; http://www.lle-inc.com/index.html [(Languag... of interpretation, translation, and language inst...
(Date:7/25/2008)... This donation will be used to facilit...ervices for children , Ha...ww.ivci.com ), a leading integrator of enterprise... video conferencing, telepresence, audio visual in...unced today that it has donated video conferencing...
(Date:7/24/2008)...N, July 24 /PRNewswire-USNewswire/ -- Speaker Nanc...ning in support of the Tom Lantos,and Henry J. Hyd..., and,Malaria Reauthorization Act of 2008. The bil...ouse this evening by a vote of 303 to 115 and will... "Today the House took an historic vote to pass l...
Breaking Medicine News(10 mins):Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...birth do survive into adolescence, a study conduct...lly it is believed that virtually all children inf.... But doctors working in sub-Saharan Africa have b...dmitted in HIV clinics. Researchers from the Well...
...bs with the NHS in the last quarter of 2006.The to...as per official statistics//. The job-cuts may be ...take a toll on patient care. Most of the redunda... category. Nevertheless, for those who have lost t...
...es cause a bizarre but dangerous side effect -- sl...n (FDA) has warned. Those who take the pills co...y may have no memory of having taken a tablet at a...g phone calls or fixing and eating food even while...
...which was in use even in ancient civilizations, ...//hospital settings. Scientists of the NHS who a...ich are taking over many hospitals across U.K, are...erial properties of this metal to use. Selly Oaks...
Other Medicine News:Health News:Trial Run of Copper to Combat MRSA 2
(Date:7/23/2008)...erapy to Treat the Disease -, WAYNE, N.J. and EME...,Bayer HealthCare Pharmaceuticals and Onyx Pharmac... The New England Journal of Medicine published,res...(R) (sorafenib),tablets decreased the absolute ris...able hepatocellular carcinoma (HCC), or liver canc...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/22/2008)...center 293-patient European, trial -, http://ww...YT, MONTREAL, July 22 / Cr...cryotherapy products to treat cardiac,arrhythmias,... from three,European study centers using the Compa... earlier today in the Journal of the American Coll...
(Date:7/22/2008)...ma Exhibits Excellent Drug-Like ...itiation of Phase II Clinical Trials -, RESEARCH ...x BioPharma,Inc., a clinical stage company develo... diseases of the central nervous system, today ann...TM) into Phase II trials for the,treatment of depr...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Novo Nordisk Settles With Pfizer On Patent Infringement Suit 8008 1CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 1CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 2CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 3CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 4CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 5CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 6CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 7Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 1Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 2Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 3Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 4FDLI PEN co sponsor major conference on nanotechnology 1536 1FDLI PEN co sponsor major conference on nanotechnology 1536 2FDLI PEN co sponsor major conference on nanotechnology 1536 3
...est, Most Comprehensive Survey Provides New Benchm...June 21, 2007 /PRNewswire-USNewswire/ -- The,follo... -- First nationwide study of the prevalence of M... (MRSA), a virulent multi-drug resistant organism,...RSA prevalence study findings significantly exceed...
...TAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- M...ill present Phase 2,data from its Unit Dose Budeso...am at the World Asthma Meeting at the Lutfi Kirdar...key. , The oral and poster presentation entitled, ... formulation of budesonide for,nebulized delivery ...
Other Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: